Compare Nomura Holdings Inc (NMR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs GeneDx Holdings Corp — how do they compare? Nomura Holdings Inc trades at $9.8 (market cap $28.69B), while GeneDx Holdings Corp trades at $81.68 (market cap $2.32B). The key difference: Nomura Holdings Inc is far larger — about 12.4× GeneDx Holdings Corp's market cap, and Nomura Holdings Inc pays a 3.3% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| NMR | WGS | |
|---|---|---|
Market Cap | $28.69B | $2.32B |
Sector | Financials | Technology |
52-Week High | $10.04 | $167.51 |
52-Week Low | $6.73 | $34.51 |
Dividend Yield | 3.3% | — |
Enterprise Value | — | $2.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.95, up 0.3% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a P/E of 11.77 and net income margin of 20.4%, supported by record annual profit in 2025. Recent Q2 2026 earnings beat expectations, and revenue growth trends upward, though cash flow from operations remains negative.
Outlook is positive with valuation appeal and earnings momentum, but risks include volatile cash flows, high debt levels, and reliance on wholesale revenue. Analysts are mixed, with 33% buy ratings. The stock presents a value opportunity amid bullish technicals, yet investors should weigh debt concerns against growth prospects.
GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.
Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
